Hemcheck was founded in 2010 by Mathias Karlsson (MD) and Hjalmar Didrikson, founder of the investment company Alfvén & Didrikson, based on an invention by Dr Karlsson. When working as a physician in clinical chemistry Mathias Karlsson clearly saw that faulty blood samples, samples that could not be analysed at the laboratory, was a major obstacle in any clinic since it required a lot of re-work and slowed down the clinical process, and hence impacted patients, staff and costs in a negative way.
How many staff members are on the team currently & do you find it difficult to find quality local and international staff?
Hemcheck has seven employees. So far, we have mainly focused on employing personnel in Sweden but that can of course change going forward. It is challenging to find competent employees and I think we have succeeded so far.
We are also able to work in a kind of a virtual organization which we consider is a strength. Myself, I live in Stockholm and our Marketing Director Peter Andersson in Helsingborg in southern Sweden. It takes a lot of video meetings, phone calls and emails, but it all works very well. When it comes to some specialized areas we use consultants.
Do any of the staff and or management team hold any shares within the company?
Yes, please visit the following homepage https://hemcheck.com/en/about/teamet/and https://hemcheck.com/en/about/teamet/.
During your time at the company, what's been your greatest achievement thus far?
I have not been long enough at the company to make that question relevant. From a company perspective I think the team has successfully managed to go all the long and sometimes tedious way from research, development and testing, to finished solutions and to the unique offerings that we now are able to take to the market, starting in Europe.
What is your medium to long-term goal & has it been consistent for some time?
We know that there is a large potential for our solutions. Our goal from a business perspective is to get a firm foothold on the European marked during the next two three years to come. Initially we will keep our focus on the Swedish market where we can work close to our customers and further develop our technology, offering and business model. Hemcheck has not yet communicated any medium or long-term financial goals but will do so as soon as it is more relevant. Right now, our focus is all about starting the market adoption by getting in paying customers.
What sets your company apart from others within your industry?
Firstly, there is no other company with a similar POC test technology and know-how that makes it possible for them to compete with Hemcheck’s unique solutions. What makes our solutions unique is that they can detect hemolysis in blood samples directly when the sample is collected at the patient side, which is long before the blood sample reaches the lab.
That contributes to improved patient safety and quality of care as well as lowered costs, shorter lead times which in turn will lead to more satisfied staff and patients.
Please share with us your favourite memory and or event since you joined the company?
I have not been long with the company, but what is really interesting is the interest we get when we are at e.g. fairs or in customer discussions. It’s clear that we bring something new that can help with a frequently occurring problem, which is really exciting.